Biomerica’s Fortel PSA Test gains approval for prostate cancer detection in UAE

The United Arab Emirates Ministry of Health and Prevention (MOHAP) has granted regulatory approval for the Fortel Prostate Specific Antigen (PSA) Screening Test, a groundbreaking diagnostic solution developed by Biomerica, Inc. This rapid screening test offers accurate results within 10 minutes using a minimally invasive finger-prick blood sample. By detecting elevated levels of PSA—an established early indicator of prostate cancer—the Fortel PSA test simplifies and accelerates the diagnostic process, providing an invaluable tool for healthcare providers and patients alike.

Prostate cancer is a pressing global health concern, ranking as the second most common cancer among men worldwide. With over 1.4 million new cases diagnosed annually and mortality rates exceeding 375,000, early detection has become a critical component of improving outcomes and saving lives.

Why Is Early Prostate Cancer Detection Critical?

Prostate cancer is often asymptomatic in its early stages, making timely screening essential for effective intervention. Elevated PSA levels, while not always indicative of cancer, are a recognized biomarker for potential prostate issues, including benign prostatic hyperplasia or prostatitis. The Fortel PSA test empowers individuals with a quick, reliable method to identify potential risks and consult medical professionals for further evaluation.

By focusing on accessibility and accuracy, Biomerica’s innovative solution is poised to significantly impact healthcare systems and reduce the strain associated with late-stage cancer diagnoses.

How Does the Fortel PSA Test Work?

The Fortel PSA Screening Test streamlines the diagnostic process, delivering laboratory-quality results in a fraction of the time required by traditional methods. Requiring only a small finger-prick blood sample, the test measures PSA levels with a sensitivity rate of 100%, a specificity rate of 95%, and an overall accuracy of 97.5%. These metrics ensure that healthcare providers can trust the results, enabling early detection and prompt intervention.

Further validation has come from studies conducted at Ain Shams University in Egypt, where the test demonstrated sensitivity, specificity, and accuracy exceeding 96%. These findings underscore its reliability as a diagnostic tool that aligns with global standards.

Addressing Prostate Cancer in the Middle East

The approval of the Fortel PSA test is part of Biomerica’s broader strategy to expand its footprint in the Middle East, a region where prostate cancer is increasingly recognized as a significant public health issue. While extensive research and advancements in early detection have been achieved in Europe and North America, the Middle East faces gaps in awareness, access to diagnostic tools, and region-specific studies.

By partnering with leading distributors and securing regulatory approvals, Biomerica aims to bring its innovative solutions to underserved populations across the UAE and beyond. This initiative follows the success of its EZ Detect Colon Disease At-Home Screening Test, which received government insurance reimbursement in Dubai.

The rising prevalence of prostate cancer in the region highlights the need for proactive measures. Factors such as aging populations, lifestyle changes, and limited public awareness contribute to the growing incidence of the disease. With the Fortel PSA test, Biomerica is addressing these challenges by offering a practical, affordable, and efficient diagnostic option.

The Broader Impact of PSA Testing on Global Health

Globally, prostate cancer continues to pose a significant challenge, with one new case diagnosed every two minutes. However, disparities in healthcare access and diagnostic availability exacerbate the burden in many regions, including parts of the Middle East. The variability in prostate cancer prevalence across ethnicities, age groups, and socioeconomic backgrounds underscores the need for tailored approaches to early detection and treatment.

Biomerica’s Fortel PSA test represents a step forward in addressing these disparities. By enabling earlier diagnoses, the test has the potential to reduce treatment costs, improve patient outcomes, and alleviate pressure on healthcare infrastructures.

What Sets Biomerica Apart in Diagnostics Innovation?

Biomerica’s commitment to advancing diagnostic solutions is evident in its strategic focus on affordability, accessibility, and accuracy. The Fortel PSA test is a testament to this vision, providing a reliable alternative to traditional screening methods without compromising quality.

The company’s efforts to expand into the Middle East reflect a broader mission to make cutting-edge healthcare solutions available globally. By prioritizing underserved regions and addressing specific healthcare challenges, Biomerica is positioning itself as a leader in diagnostics innovation.

Looking Ahead: A Commitment to Better Health

The approval of the Fortel PSA test in the UAE marks a milestone in Biomerica’s journey to revolutionize cancer detection. As prostate cancer rates rise, the availability of rapid, reliable screening tools will be pivotal in reducing mortality and improving quality of life for patients.

Biomerica’s focus on expanding access to diagnostics in the Middle East aligns with global efforts to combat cancer through early detection. By bridging gaps in healthcare delivery, the company is contributing to a future where life-saving tools are within reach for all.